View Exam | PowerPak

1. Which of these patients with advanced non–small cell lung cancer (NSCLC) is more likely to have a KRAS G12C mutation?

A. 61-year-old Asian female, never smoker with metastatic adenocarcinoma B. 73-year-old Caucasian female, former light smoker with metastatic squamous cell carcinoma C. 52-year-old African American male, current heavy smoker with metastatic squamous cell carcinoma D. 64-year-old Caucasian male, former heavy smoker with metastatic adenocarcinoma E. Unsure

2. Amivantamab is a novel, fully human bispecific antibody developed for treatment of advanced NSCLC that targets which 2 key proteins?

A. PD-1 and PD-L1 B. EGFR and MET C. ALK and ROS1 D. HER2 and RET E. Unsure

3. Your 60-year-old Asian female patient with metastatic adenocarcinoma NSCLC who has progressed on first-line, platinum-based chemotherapy is found to have an EGFR exon 20 insertion mutation. Her past medical history is significant for atrial fibrillation, gastroesophageal reflux disease (GERD), and depression. She is currently on metoprolol succinate 100 mg PO daily, pantoprazole 40 mg PO daily, and citalopram 40 mg PO daily. A baseline EKG reveals a QTc of 492. Which is the best treatment option for this patient?

A. Mobocertinib B. Capmatinib C. Amivantamab D. Sotorasib E. Unsure

4. Your patient with metastatic adenocarcinoma NSCLC is about to begin treatment with sotorasib. Based on the frequency of adverse effects seen in clinical trials, you inform him that he may experience which of the following?

A. Diarrhea B. Ocular toxicities C. Infusion reactions D. Renal toxicity E. Unsure

5. For patients with advanced NSCLC, biomarker testing ideally should be performed:

A. As soon as possible following diagnosis B. At time of first relapse C. Only in individuals who have progressed on immune checkpoint inhibitors (ICIs) D. In patients who are not positive for PD-1 or PD-L1 E. Unsure

6. For suspected genomic alterations in patients with advanced NSCLC, the preferred assessment methodology is:

A. Fluorescent in situ hybridization (FISH) B. Immunohistochemistry (IHC) C. Next-generation sequencing (NGS) D. Determination of tumor mutation burden (TMB) E. Unsure

7. In the GEOMETRY mono-1 phase 2 trial of capmatinib in patients with MET-dysregulated advanced NSCLC, efficacy was greatest in which subgroup?

A. Those also bearing an EGFR mutation B. Patients with a MET exon 14 skipping mutation and 1 to 2 lines of prior therapy C. Treatment-naïve patients with a MET exon 14 skipping mutation D. Those with MET gene amplification E. Unsure

8. The tyrosine kinase inhibitor (TKI) tepotinib is now approved as a treatment option for patients with advanced or metastatic NSCLC whose tumors bear a(n):

A. ALK rearrangement B. EGFR exon 20 insertion mutation C. MET exon 14 skipping alteration D. NTRK1/2/3 gene fusion E. Unsure

9. EGFR exon 20 insertion mutations in advanced NSCLC are clinically relevant because they are associated with which of the following?

A. Higher response rates to standard approved EGFR TKIs such as osimertinib B. Superior survival compared with EGFR exon 19 deletions and exon 21 L858R point substitutions C. Response to ICIs D. Resistance to standard approved EGFR TKIs E. Unsure

10. For orally administered targeted agents, pharmacists can monitor and support patient adherence to the prescribed dosing regimen. This is important since poor adherence can lead to:

A. Higher relative dose intensity B. More comorbidities C. Increased drug-drug interactions D. Poorer outcomes and higher costs E. Unsure

Evaluation Questions

11. How confident are in your treatment choices for the patients in the posttest?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of these patients with advanced non–small cell lung cancer (NSCLC) is more likely to have a KRAS G12C mutation?

2. Amivantamab is a novel, fully human bispecific antibody developed for treatment of advanced NSCLC that targets which 2 key proteins?

4. Your patient with metastatic adenocarcinoma NSCLC is about to begin treatment with sotorasib. Based on the frequency of adverse effects seen in clinical trials, you inform him that he may experience which of the following?

5. For patients with advanced NSCLC, biomarker testing ideally should be performed:

6. For suspected genomic alterations in patients with advanced NSCLC, the preferred assessment methodology is:

7. In the GEOMETRY mono-1 phase 2 trial of capmatinib in patients with MET-dysregulated advanced NSCLC, efficacy was greatest in which subgroup?

8. The tyrosine kinase inhibitor (TKI) tepotinib is now approved as a treatment option for patients with advanced or metastatic NSCLC whose tumors bear a(n):

9. EGFR exon 20 insertion mutations in advanced NSCLC are clinically relevant because they are associated with which of the following?

10. For orally administered targeted agents, pharmacists can monitor and support patient adherence to the prescribed dosing regimen. This is important since poor adherence can lead to:

Evaluation Questions

11. How confident are in your treatment choices for the patients in the posttest?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of these patients with advanced non–small cell lung cancer (NSCLC) is more likely to have a KRAS G12C mutation?

2. Amivantamab is a novel, fully human bispecific antibody developed for treatment of advanced NSCLC that targets which 2 key proteins?

4. Your patient with metastatic adenocarcinoma NSCLC is about to begin treatment with sotorasib. Based on the frequency of adverse effects seen in clinical trials, you inform him that he may experience which of the following?

5. For patients with advanced NSCLC, biomarker testing ideally should be performed:

6. For suspected genomic alterations in patients with advanced NSCLC, the preferred assessment methodology is:

7. In the GEOMETRY mono-1 phase 2 trial of capmatinib in patients with MET-dysregulated advanced NSCLC, efficacy was greatest in which subgroup?

8. The tyrosine kinase inhibitor (TKI) tepotinib is now approved as a treatment option for patients with advanced or metastatic NSCLC whose tumors bear a(n):

9. EGFR exon 20 insertion mutations in advanced NSCLC are clinically relevant because they are associated with which of the following?

10. For orally administered targeted agents, pharmacists can monitor and support patient adherence to the prescribed dosing regimen. This is important since poor adherence can lead to:

Evaluation Questions

11. How confident are in your treatment choices for the patients in the posttest?

« Return to Activity

Customers who Purchased
this Activity also Purchased